J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

/PRNewswire/ — J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from…Read More

What's Trending

How Microsoft Pulled off ‘One of the Best Tech Acquisitions of the Last Decade’

KU softball drops to Texas Tech in Big 12 semifinal

Bee more specific: New radar tech could improve identification and tracking of key pollinators

Tourism funding cut for Key West Pride event as county cites state DEI law

Tucson law firm protest over Project Blue draws criticism

Gorsuch Pitches Kids Book to Right, Insisting Court Nonpartisan

Inside the fight to undo a century‑old law blamed for soaring infrastructure costs

White Shoe Law Firms Are Haggling Over London’s Distressed Experts

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

FIFA WC 2026: DR Congo to camp in Europe

Exclusive Culturally Immersive Travel Experiences Now Available in Thailand as Visa Expands Its Global Travel Programme to Asia Pacific – Travel And Tour World

Visa Destinations Launches in Asia Pacific: Thailand and Singapore to Offer Exclusive Travel Experiences in 2026 – Travel And Tour World

Europe Day: 40 years of ups and downs in Spain’s relationship with the European Union

Leave A Reply Cancel Reply

What's Trending

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

Related Posts

Leave A Reply Cancel Reply

Subscribe to MGSN